Chapter 1 · Cardiovascular Medicine · Lesson 3
Coronary artery disease: chronic and acute coronary syndromes
Fellowship-level theory for the RACGP AKT and KFP, built on the 2025 Australian ACS guideline and current chronic coronary syndrome evidence.
Acute coronary syndromes: the National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (CSANZ) published a new Australian Clinical Guideline for Diagnosing and Managing Acute Coronary Syndromes 2025, replacing the 2016 guideline. A summary appeared in the Medical Journal of Australia in February 2026.1,2 Answer exam questions from the 2025 guideline. Many textbooks and older notes still teach the 2016 values (section 9).
CT coronary angiography (CTCA): Medicare item 57360 still requires the request to come from a specialist or consultant physician.7 A GP-requestable CTCA item has been proposed (consultation in 2024) but was not listed as at November 2026.8 Check MBS Online before advising patients on costs.
- Feb 2026: MJA summary of the 2025 Heart Foundation/CSANZ ACS guideline.2
- 2025: new Australian ACS guideline: “acute coronary occlusion myocardial infarction” (ACOMI) terminology, oxygen only if SpO2 <90%, primary PCI preferred if achievable within 120 minutes, LDL-C target <1.4 mmol/L, fewer routine beta-blockers, long-term P2Y12 inhibitor preferred after DAPT.1
- Aug 2024: ESC chronic coronary syndromes guideline: a risk-factor-weighted pre-test likelihood model and CTCA preferred to rule out obstructive disease.4
- Jun 2024: GP-requested CTCA item proposed by the Department of Health (not yet listed).8
Each statement below was standard teaching under the 2016 Australian ACS guideline. Decide whether it is still true before you tap.
Give oxygen in suspected ACS if the SpO2 is below 93%.
After an ACS, aim for an LDL-C below 1.8 mmol/L.
Every patient needs a beta-blocker indefinitely after a myocardial infarction.
Primary PCI is preferred only if it can be done within 90 minutes of first medical contact.
Cold-start check
Answer these questions before you read the lesson. Getting some wrong is the point: attempting questions before studying helps you remember the answers afterwards, and your score tells you where to spend your time.
1. In suspected ACS, below which SpO2 should oxygen be given?
90%. No oxygen if SpO2 is ≥90%, and do not exceed 96% if you give it. Read 6.3 Immediate management →
2. What is the initial LDL-C target after an ACS?
<1.4 mmol/L and at least 50% lower than baseline. Recheck lipids 4–6 weeks after starting or changing treatment. Read 7.1 Medicines after ACS →
3. In ACOMI (STEMI), primary PCI is preferred over fibrinolysis if it can be performed within how long of first medical contact?
120 minutes. If PCI cannot be delivered within 120 minutes, give fibrinolysis within 30 minutes of first medical contact. Read 6.4 Reperfusion →
4. After dual antiplatelet therapy finishes, which long-term single antiplatelet does the 2025 guideline prefer?
A P2Y12 inhibitor. A new recommendation: long-term P2Y12 inhibitor monotherapy is preferred over aspirin. Read 7.1 Medicines after ACS →
5. The Heart Foundation action plan says to call 000 if symptoms are severe, getting worse, or have lasted how long?
10 minutes. Rest, take angina medicine every 5 minutes, chew aspirin 300 mg unless contraindicated, and call 000. Read 5.3 Using GTN →
Your score: / 5
| Score | What to do |
|---|---|
| 5 / 5 | Strong start. Skim the key takeaways, then go straight to the self-check questions. |
| 3–4 / 5 | Read the sections linked from the questions you missed, then do the self-check. |
| 0–2 / 5 | Work through the whole lesson. Your notes are probably based on the 2016 guideline — check the old-notes box above. |
Learning objectives
- Assess acute and chronic chest pain in general practice and decide who needs emergency transfer.
- Recognise ACOMI (STEMI and STEMI-equivalent) ECG patterns using the 2025 thresholds.
- Give correct immediate treatment for suspected ACS in the practice, including in rural settings.
- Choose investigations and treatment for chronic coronary syndromes, including antianginal drugs under constraints.
- Manage secondary prevention after ACS: antiplatelets, lipids, beta-blockers, rehabilitation, driving and return to activity.
How this is examined
- AKT: ECG thresholds, reperfusion time targets, DAPT duration, triple therapy with AF, antianginal contraindications, nitrate–PDE5 interactions, Austroads driving periods.
- KFP: “list your immediate management” in the practice, “most appropriate next step” after a normal ECG or troponin, discharge medicine lists, safety advice.
- Common trap: treating pericarditis as an MI (and the reverse), giving routine oxygen, or sending a patient with possible ACS home after one normal test.
Every section carries a GP Institute study-priority rating. It is our editorial judgement, based on the RACGP curriculum, how heavily current Australian guidelines emphasise the topic, patient safety, recent changes, and the themes in published RACGP exam reports. It is not an official RACGP weighting, and any topic can be examined.
| Rating | What it means for your study |
|---|---|
| ★★★★ | Must know. Core, frequently examined, safety-critical or recently changed. Know it cold, without notes. |
| ★★★☆ | High yield. Commonly tested; know the thresholds, drugs and next steps. |
| ★★☆☆ | Know the principles. Understand the reasoning; detailed numbers are less likely to be asked. |
| ★☆☆☆ | Background. Read once for context. |
- 3. Assessing chest pain in general practice
- 3.3 The GP decision: is this an ACS now?
- 5. Chronic coronary syndromes: management
- 5.2 Antianginal drugs
- 5.3 Using GTN, and the PDE5 inhibitor interaction
- 6. Acute coronary syndromes
- 6.1 The ECG: ACOMI patterns
- 6.3 Immediate management in the practice
- 6.4 Reperfusion in ACOMI
- 7. After an ACS: the GP’s role
- 7.1 Medicines after ACS
- 7.3 Driving, work, sex and travel
- 9. Old versus new guidance
1. Why it matters ★☆☆☆
Coronary heart disease remains the leading single cause of death in Australia, and most of the burden falls outside hospital: in the years of stable angina before an event, in the minutes between symptom onset and the ambulance, and in the decades of secondary prevention afterwards.17 General practice owns three of these four phases. The GP diagnoses chronic coronary disease, is often the first medical contact in an acute coronary syndrome (especially in rural Australia), and runs the long-term medicines, risk factor control and rehabilitation that decide whether a second event happens.
Ischaemic heart disease is a spectrum (Figure 1). At one end are chronic coronary syndromes (CCS): predictable exertional angina from fixed stenoses, angina with non-obstructive coronary arteries, and stable disease after a previous event or revascularisation. At the other end are acute coronary syndromes (ACS), where plaque rupture or erosion causes thrombosis. The urgency, the tests and the drugs change completely as a patient moves along the spectrum, and many exam questions are really asking “where on this spectrum is the patient now?”
↔ Swipe sideways to see the whole figure
2. Pathophysiology and terminology ★★☆☆
Atherosclerosis begins with endothelial dysfunction, which lets LDL particles enter the arterial wall. The lipid is oxidised and taken up by macrophages (foam cells), smooth muscle migrates in, and a plaque with a lipid core and fibrous cap develops. Two kinds of plaque behave very differently. A thick-capped, stable plaque narrows the lumen and limits flow when demand rises, giving predictable exertional angina. A thin-capped, inflamed plaque may cause little narrowing but can rupture or erode, exposing thrombogenic material; platelet aggregation and thrombus then cause an ACS. This is why a normal stress test does not rule out a future infarct, and why statins, antiplatelets and colchicine (which act on lipid, platelets and inflammation) prevent events, while antianginal drugs mainly relieve symptoms.
2.1 Myocardial injury and types of infarction ★★★☆
The Fourth Universal Definition of Myocardial Infarction separates myocardial injury (any cardiac troponin above the 99th percentile upper reference limit) from myocardial infarction (an acute injury, shown by a rise or fall in troponin, with clinical evidence of ischaemia).11 The type of infarction decides the treatment, so examiners expect you to know it.
| Category | Mechanism | Typical examples | Management focus |
|---|---|---|---|
| Type 1 MI | Plaque rupture or erosion with thrombosis | Classic ACS | Antithrombotic therapy, angiography, revascularisation |
| Type 2 MI | Supply–demand mismatch without acute thrombosis | Tachyarrhythmia, severe anaemia, hypotension, hypoxia, sepsis | Treat the cause; look for underlying coronary disease later |
| Types 3–5 | Sudden cardiac death before troponin; PCI-related; CABG-related | Procedural MI | Specialist |
| Acute non-ischaemic injury | Troponin rise and fall without ischaemia | Myocarditis, Takotsubo, pulmonary embolism, sepsis | Diagnose the cause |
| Chronic injury | Stable, persistently raised troponin | CKD, heart failure, LVH | Interpret serial values: a stable level is not an MI |
2.2 New terminology: ACOMI ★★★☆
ST elevation is an imperfect marker of an occluded artery. Some occlusions (posterior infarction, De Winter T waves, infarction with left bundle branch block or a paced rhythm) do not produce classic ST elevation, and some ST elevation is not an occlusion (early repolarisation, pericarditis, LV aneurysm). The 2025 Australian guideline therefore uses acute coronary occlusion myocardial infarction (ACOMI) for STEMI and STEMI-equivalent patterns. Every ACOMI activates the reperfusion pathway. The rest of ACS is non-ST-segment elevation ACS (NSTEACS): NSTEMI if troponin rises above the 99th percentile, unstable angina if it does not.1 The guideline also classes infarction caused by spontaneous coronary artery dissection (SCAD), coronary embolism and vasospasm as occlusive MI.
The ECG decides the pathway; troponin does not. In a patient with ongoing pain and an occlusion pattern, never wait for troponin before arranging reperfusion. A normal ECG and a normal first troponin also do not exclude an ACS (section 6.2).
3. Assessing chest pain in general practice ★★★★
Chest pain in general practice is usually not cardiac. The task is not to make a final diagnosis in the consulting room but to answer one question first: could this be an acute coronary syndrome, or another time-critical cause, right now? If yes, the patient goes by ambulance with treatment started. If no, there is time for a planned work-up.
3.1 The history ★★★☆
Angina is typically a retrosternal pressure, heaviness or tightness that may radiate to the arms, neck, jaw or back, is provoked by exertion or emotion, and settles within minutes of rest or GTN. In an ACS the same discomfort is new, occurs at rest, is increasing (crescendo), or lasts longer than about 10–20 minutes, often with sweating, nausea or breathlessness. Pain that is sharp, positional, pleuritic, reproducible on palpation or lasting only seconds is less likely to be ischaemic, but none of these features excludes it.
Atypical presentations are common in women, older people, people with diabetes or CKD, and people with dementia. Breathlessness, fatigue, epigastric discomfort, dizziness or confusion may be the only symptom. The 2025 guideline notes that chest pain is still the most common symptom in women, but that women are more often misdiagnosed; consider SCAD in younger and middle-aged women.1 Ask about cocaine and amphetamine use in younger patients.
| Feature | Points towards ischaemia | Points away (but does not exclude) |
|---|---|---|
| Character | Pressure, heaviness, tightness, burning, “indigestion” | Sharp, stabbing, fleeting, pricking |
| Site and radiation | Retrosternal; to both arms, jaw, neck or back | Small, well-localised spot; pointed to with one finger |
| Trigger | Exertion, cold, emotion, after meals | Movement of the chest wall, breathing, pressure on the area |
| Duration | Minutes (stable angina); >10–20 minutes or at rest (ACS) | Seconds, or constant for days |
| Relief | Rest or GTN within minutes | Antacids, change of posture (GTN relief does not separate oesophageal spasm from angina) |
| Associated | Sweating, nausea, breathlessness, syncope | Fever, cough, rash in a dermatome |
| Context | Known coronary disease, diabetes, smoking, family history, CKD, First Nations heritage, stimulant use | Young, no risk factors, clear alternative cause |
3.2 The dangerous differentials ★★★☆
Five other conditions can kill within hours and must be considered in every acute chest pain. Some of them make standard ACS treatment harmful: antiplatelets and fibrinolysis in aortic dissection, or anticoagulation in a dissection mistaken for pulmonary embolism.
| Diagnosis | Clues | ECG and tests | Treatment trap |
|---|---|---|---|
| ACS | Pressure-like pain, risk factors, sweating | ACOMI pattern, ST depression, T-wave inversion or normal; troponin rise | A normal first ECG or troponin does not exclude it |
| Aortic dissection | Sudden tearing pain to the back, pulse or BP difference between arms, new aortic regurgitation, neurological signs | May show inferior ST elevation if the right coronary ostium is involved | Fibrinolysis and antiplatelets can be fatal |
| Pulmonary embolism | Pleuritic pain, breathlessness, tachycardia, hypoxia, risk factors | Sinus tachycardia, right heart strain; troponin may rise | Missed when troponin is assumed to mean MI |
| Tension pneumothorax | Sudden pain and breathlessness, absent breath sounds, tracheal shift | Clinical diagnosis | Do not wait for an X-ray |
| Cardiac tamponade | Hypotension, raised JVP, muffled heart sounds, pulsus paradoxus | Low voltage, electrical alternans | Nitrates can cause collapse |
| Oesophageal rupture | Pain after vomiting, subcutaneous emphysema | Chest X-ray, CT | Rare; easily mistaken for MI |
| Acute pericarditis (not usually time-critical) | Sharp pain, worse lying flat, better sitting forward, rub | Widespread concave ST elevation with PR depression | Do not give fibrinolysis; treat with NSAID plus colchicine |
3.3 The GP decision: is this an ACS now? ★★★★
A 12-lead ECG should be recorded and interpreted within 10 minutes of first clinical contact.1 In the practice, that means doing the ECG before taking a full history if the story sounds acute. Figure 2 shows the decision sequence. The key principle: the GP’s job is to identify possible ACS, start treatment and transfer, not to rule ACS out. Ruling out needs serial high-sensitivity troponin and a structured risk score, which happens in the emergency department.
- Ongoing pain, pain at rest for more than 10 minutes, or a crescendo pattern → possible ACS.
- Hypotension, new arrhythmia, syncope, breathlessness or signs of heart failure.
- Any ACOMI pattern on the ECG (Table 7), including posterior and LBBB/paced patterns.
- Tearing pain to the back or unequal arm pulses → possible dissection: no antiplatelets or fibrinolysis until it is excluded.
- Never send a patient with possible ACS by private car or let them drive themselves.
4. Chronic coronary syndromes: diagnosis ★★★☆
A patient with stable exertional symptoms needs three things: an estimate of how likely obstructive coronary disease is, a test chosen to answer the question that matters for that patient, and treatment that starts before the test result returns. Antiplatelet and statin decisions depend on the diagnosis. Antianginal drugs and the action plan should not wait for the test.
4.1 Pre-test likelihood and choosing a test ★★★☆
The 2024 ESC guideline estimates the clinical likelihood of obstructive coronary disease from age, sex, the nature of the symptoms and the number of risk factors (family history, smoking, dyslipidaemia, hypertension, diabetes). This “risk-factor-weighted clinical likelihood” is then adjusted for the resting ECG, any coronary calcium score and other findings.4 There is no Australian chronic coronary syndrome guideline of equivalent detail; Therapeutic Guidelines and Australian cardiologists use the same principles.5
| Likelihood | Usual approach | Comment |
|---|---|---|
| Very low (≤5%) | Consider deferring testing | Look for other causes of the symptoms; treat risk factors |
| Low (>5–15%) | Consider a coronary calcium score or CTCA | The best strategy is less certain because few trials studied this group |
| Moderate (>15–50%) | CTCA (preferred to rule out obstructive disease) or functional imaging | The group most diagnostic studies enrolled |
| High (>50–85%) | Functional imaging (stress echocardiography, perfusion imaging, stress cardiac MRI) | Links symptoms to ischaemia and guides revascularisation |
| Very high (>85%), or very severe or unstable features | Invasive coronary angiography | Usually via a cardiologist |
Choose CTCA when the main question is “is there obstructive disease?” and the patient can have it (stable heart rate in sinus rhythm, adequate kidney function, no contrast allergy, able to hold their breath). Choose functional imaging when the question is “is this coronary disease causing these symptoms?”, for example with known coronary disease or intermediate stenoses. Exercise ECG on its own has lower accuracy, but it is widely available, can be useful in rural practice, and gives prognostic information about exercise capacity.
4.2 Tests and Medicare access ★★★☆
| Test | Best use | Limitations | Access |
|---|---|---|---|
| Resting 12-lead ECG | Everyone: previous MI (Q waves), LVH, conduction disease, arrhythmia | Often normal in stable angina | GP |
| Bloods | FBC (anaemia), lipids, HbA1c, UEC and eGFR, TSH if indicated | Troponin is not a test for stable angina | GP |
| Exercise stress ECG | Able to exercise and a normal resting ECG | Lower sensitivity; uninterpretable with LBBB, paced rhythm, digoxin or major ST changes | GP request (MBS rules apply) |
| Stress echocardiography (exercise or dobutamine) | Functional imaging; dobutamine if unable to exercise | Operator-dependent; poor windows | GP request |
| Myocardial perfusion scan | Functional imaging when echo windows are poor | Radiation; availability | GP request |
| CT coronary angiography (CTCA) | Ruling out obstructive disease at low–moderate likelihood | Needs a slow, regular heart rate, contrast and radiation; calcium causes artefact | MBS item 57360 requires a specialist or consultant physician request; GP-requested CTCA is privately billed7 |
| Coronary artery calcium score | Adjusts likelihood; risk reclassification in asymptomatic people | Does not show non-calcified plaque or stenosis | Not Medicare-funded |
| Invasive coronary angiography | Very high likelihood, refractory symptoms, high-risk non-invasive result, planning revascularisation | Invasive; small risk of stroke, bleeding, contrast nephropathy | Cardiologist |
4.3 Diagnostic pathway ★★☆☆
5. Chronic coronary syndromes: management ★★★★
Management has two separate goals, and exam questions often test whether you know which drug serves which goal. Event prevention (antiplatelets, statins, BP and diabetes control, smoking cessation, ACE inhibitors in selected patients, colchicine) reduces MI and death. Symptom relief (antianginal drugs and, in some patients, revascularisation) improves quality of life but in most stable patients does not prolong life.
5.1 Preventing events ★★★☆
| Measure | Recommendation | Notes |
|---|---|---|
| Single antiplatelet | Aspirin 100 mg daily (or clopidogrel 75 mg if aspirin is not tolerated)4,5 | For confirmed obstructive disease. Not for primary prevention in most people |
| Statin | High-intensity statin; same targets as after ACS (LDL-C <1.4 mmol/L and ≥50% reduction) for very high-risk patients | See Lesson 2 for ezetimibe and PCSK9 steps |
| ACE inhibitor or ARB | If hypertension, diabetes, CKD or LVEF ≤40% | Not routinely for every patient with normal LV function |
| Colchicine 0.5 mg daily | Consider in stable coronary disease (LoDoCo2) and after ACS1,13 | Avoid in significant kidney or liver impairment; interactions with strong CYP3A4/P-glycoprotein inhibitors (e.g. clarithromycin) |
| Low-dose rivaroxaban plus aspirin | Selected high-ischaemic, low-bleeding-risk patients with coronary or peripheral disease (COMPASS: 2.5 mg twice daily plus aspirin)14 | Specialist-guided; check current PBS criteria |
| Risk factors | Stop smoking; BP <130/80 mmHg if tolerated; individualised HbA1c; physical activity; healthy weight | See Lesson 1 |
| Vaccination | Annual influenza vaccine; other respiratory vaccines as per the Immunisation Handbook | Recommended in the 2025 ACS guideline |
5.2 Antianginal drugs ★★★★
First-line prevention of angina is a beta-blocker or a calcium channel blocker, chosen to suit the patient’s heart rate, BP, LV function and other conditions. If symptoms persist, the usual step is to combine a beta-blocker with a dihydropyridine calcium channel blocker (amlodipine, felodipine). Verapamil and diltiazem should not be combined with a beta-blocker because of bradycardia and heart block. Long-acting nitrates, nicorandil, ivabradine and ranolazine are second-line or add-on options.4,5
| Drug | Best when | Avoid or caution | Examinable adverse effects |
|---|---|---|---|
| Beta-blocker (metoprolol, atenolol, bisoprolol) | Post-MI with LV impairment, AF, heart failure with reduced EF | Bradycardia, heart block, severe asthma, vasospastic angina | Fatigue, cold peripheries, erectile dysfunction, masked hypoglycaemia |
| Dihydropyridine CCB (amlodipine, felodipine) | Hypertension; combined with a beta-blocker; asthma | Severe aortic stenosis; short-acting nifedipine (reflex tachycardia) | Ankle oedema, flushing, headache |
| Rate-limiting CCB (verapamil, diltiazem) | Beta-blocker contraindicated (e.g. asthma); vasospastic angina | With a beta-blocker; LVEF ≤40%; heart block | Constipation (verapamil), bradycardia; many interactions (CYP3A4) |
| Long-acting nitrate (isosorbide mononitrate, GTN patch) | Add-on; vasospastic angina | PDE5 inhibitors; severe aortic stenosis; hypertrophic obstructive cardiomyopathy | Headache, hypotension; tolerance without a daily nitrate-free interval |
| Nicorandil | Add-on when others are not tolerated | PDE5 inhibitors; hypotension | Ulceration (mouth, anus, bowel, skin); stop if ulcers develop |
| Ivabradine | Sinus rhythm with resting heart rate ≥70/min despite or instead of a beta-blocker | AF; with verapamil or diltiazem; strong CYP3A4 inhibitors; pregnancy | Visual phosphenes, bradycardia |
| Ranolazine | Add-on; does not lower heart rate or BP | QT prolongation; strong CYP3A4 inhibitors; severe kidney impairment | Dizziness, constipation |
An antianginal question is usually a constraints question. Read the stem for heart rate (ivabradine needs ≥70/min in sinus rhythm), LVEF (no verapamil or diltiazem if reduced), asthma (no beta-blocker if severe), erectile dysfunction treatment (no nitrates or nicorandil with a PDE5 inhibitor) and BP (amlodipine helps if hypertensive; avoid adding vasodilators if already hypotensive).
5.3 Using GTN, and the PDE5 inhibitor interaction ★★★★
Every patient with angina should have short-acting GTN (sublingual spray 400 micrograms per dose, or tablets) and a written plan. GTN tablets lose potency once the bottle is opened, so they are usually discarded 3 months after opening; sprays last longer. Teach the patient to sit down before using it (it can cause hypotension and syncope) and to use it before exertion that reliably brings on angina.
| Step | What the patient does |
|---|---|
| 1. Stop and rest | Stop what you are doing and sit or lie down. Tell someone how you feel. |
| 2. Angina medicine | If prescribed, take a dose. Wait 5 minutes; if symptoms persist, take another dose. |
| 3. Call 000 | If symptoms are severe, getting worse, or have lasted 10 minutes, call 000 for an ambulance. Do not hang up. |
| 4. Aspirin | Chew aspirin 300 mg unless allergic or told not to by a doctor. |
The action plan above is the Heart Foundation’s patient wording.10 Health professionals treating ongoing ischaemic pain can give sublingual GTN every 5 minutes for up to three doses if there are no contraindications.1
- Do not give nitrates (or nicorandil) within 24 hours of sildenafil or vardenafil, or within 48 hours of tadalafil: profound hypotension can occur.6
- Ask every man with chest pain about erectile dysfunction medicines before giving GTN, and record the answer.
- Also withhold GTN if systolic BP is low, in suspected right ventricular infarction with hypotension, and in severe aortic stenosis.
5.4 When revascularisation helps ★★☆☆
In stable patients with normal LV function and no left main or proximal LAD disease, revascularisation does not prolong life compared with optimal medical therapy; the ISCHEMIA trial showed no reduction in death or MI from a routine invasive strategy, though angina improved.12 Revascularisation is mainly for symptoms that persist despite optimal medical therapy (usually at least two antianginal drugs). It has a prognostic role in significant left main disease, functionally significant multivessel disease, and ischaemic LV dysfunction, where CABG prolongs survival in the long term. CABG is generally preferred over PCI for complex multivessel disease, especially with diabetes.4 Decisions are made by a Heart Team. The GP’s role is to refer when symptoms are uncontrolled or non-invasive testing shows high-risk features, and to make sure medical therapy is truly optimised first.
5.5 Vasospastic angina and ANOCA/INOCA ★★☆☆
Vasospastic (Prinzmetal) angina causes rest pain, often at night or early morning, with transient ST elevation that resolves with nitrates. Smoking, cocaine, amphetamines, triptans and cold are triggers. Treat with a calcium channel blocker (first line) and nitrates, stop smoking, and avoid non-selective beta-blockers, which can make spasm worse. Angina or ischaemia with non-obstructive coronary arteries (ANOCA/INOCA), from microvascular dysfunction or vasospasm, is common, especially in women, and is not benign. Patients who remain symptomatic despite treatment should be referred for invasive coronary function testing.4
6. Acute coronary syndromes ★★★★
An ACS is diagnosed from symptoms, the ECG and troponin, in that order of urgency. The ECG sorts patients into ACOMI (reperfusion now) and possible NSTEACS (antithrombotic therapy, serial troponin and risk stratification). This section covers what an exam expects a GP to know and to do, including in rural and remote settings, where the GP may be the doctor who gives fibrinolysis.
6.1 The ECG: ACOMI patterns ★★★★
| Pattern | Criterion | Tip |
|---|---|---|
| ST elevation, leads other than V2–V4 | ≥1 mm in two contiguous leads | Look for reciprocal ST depression |
| ST elevation, V2–V4 | Women: ≥1.5 mm. Men aged ≥40 years: ≥2 mm | The sex-specific threshold is a common exam trap |
| Posterior MI | ST depression ≥0.5 mm in V1–V3 | Confirm with posterior leads V7–V9 |
| Right ventricular MI | ST elevation ≥0.5 mm in right-sided leads (V3R–V6R) | Record right-sided leads in every inferior MI; avoid nitrates if hypotensive |
| De Winter pattern | Upsloping ST depression with tall, symmetrical T waves in the precordial leads | Proximal LAD occlusion without ST elevation |
| LBBB or ventricular paced rhythm | Modified Sgarbossa criteria | New LBBB alone is no longer automatically “STEMI”; use the criteria |
Source: Heart Foundation/CSANZ 2025.1 Repeat the ECG every 15–30 minutes while pain continues or if symptoms change: occlusion can evolve. Continuous cardiac monitoring and a defibrillator should be available while ACOMI is being assessed.
| Territory | Leads with ST elevation | Usual artery | Watch for |
|---|---|---|---|
| Anterior / anteroseptal | V1–V4 | Left anterior descending | Large infarct, heart failure, VT/VF |
| Lateral | I, aVL, V5–V6 | Circumflex or diagonal | Often subtle |
| Inferior | II, III, aVF | Right coronary (most), circumflex | Bradycardia and heart block; RV infarction |
| Posterior | ST depression V1–V3; elevation V7–V9 | Circumflex or right coronary | Easily missed as “anterior ischaemia” |
| Right ventricle | V4R (and V3R–V6R) | Proximal right coronary | Hypotension with clear lungs and raised JVP: give fluids, avoid nitrates |
6.2 High-sensitivity troponin ★★★☆
The 2025 guideline strongly recommends high-sensitivity cardiac troponin (hs-cTn) for everyone with suspected ACS, interpreted within a clinical decision pathway: a 0/1-hour or 0/2-hour strategy (the 0/2-hour strategy is the most practical in most Australian settings) or the High-STEACS algorithm, combined with a formal risk score such as EDACS or HEART. Thresholds are assay-specific, the upper limit is the sex-specific 99th percentile, and deltas can only be compared between results from the same assay. A single hs-cTn measurement is not suitable when symptoms began less than 2 hours earlier.1
| Situation | Interpretation | What to do |
|---|---|---|
| Normal result within 2 hours of symptom onset | Too early to exclude MI | Repeat per the pathway in the ED |
| Point-of-care troponin negative in the practice | Most point-of-care assays are less sensitive than laboratory hs-cTn | Does not exclude ACS; transfer if the story is suggestive |
| Rising or falling values above the 99th percentile with ischaemic symptoms | Acute MI | Manage as NSTEMI unless the ECG shows ACOMI |
| Stable, mildly raised values (e.g. CKD, heart failure) | Chronic myocardial injury | Not an MI by itself; compare with previous results |
| Rise with a clear non-coronary cause | Type 2 MI or non-ischaemic injury | Treat the cause (Table 1) |
6.3 Immediate management in the practice ★★★★
Treatment starts as soon as ACS is suspected, not when it is confirmed. The list below is the “immediate management” answer KFP questions look for. Write it specifically: “aspirin 300 mg chewed”, not “antiplatelet”.
| Action | Detail | Avoid |
|---|---|---|
| Call 000 | Ambulance transfer with monitoring; transmit the ECG if possible | Private car; the patient driving |
| Aspirin | 300 mg orally, chewed or dissolved, unless contraindicated | Delaying until troponin is known; giving it in suspected aortic dissection |
| ECG and monitoring | 12-lead ECG within 10 minutes, repeated if pain continues; defibrillator ready | Leaving the patient alone |
| Oxygen | Only if SpO2 <90%; keep SpO2 ≤96% | Routine oxygen in a well-saturated patient |
| GTN | Sublingual every 5 minutes, up to 3 doses, if pain persists and there is no contraindication | Hypotension, RV infarction, PDE5 inhibitor use, severe aortic stenosis |
| Analgesia | IV fentanyl or morphine boluses for ongoing pain (reasonable) | NSAIDs (increase major adverse cardiac events) |
| IV access | If skills allow; take bloods for the receiving team | Intramuscular injections if fibrinolysis is possible |
| Communicate | Time of symptom onset, ECG, drugs and doses given, allergies | Delay to write a long referral |
P2Y12 inhibitors and anticoagulants are usually started by the ambulance service or hospital according to the reperfusion strategy. A GP in a rural or remote setting may give them as part of a local protocol, often with telehealth support from the regional cardiology or retrieval service.1
6.4 Reperfusion in ACOMI ★★★★
Primary PCI and fibrinolysis are both effective within 12 hours of symptom onset; PCI is better when it can be delivered quickly. The 2025 guideline gives a simple rule: primary PCI if it can be performed within 120 minutes of first medical contact; otherwise fibrinolysis within 30 minutes of first medical contact, with prehospital fibrinolysis considered. Beyond 12 hours, primary PCI is still indicated if ischaemia is ongoing.1
| Absolute | Relative |
|---|---|
| Any previous intracranial haemorrhage; ischaemic stroke in the past 3 months; known intracranial tumour or vascular malformation; suspected aortic dissection; active bleeding (not menses); significant head or facial trauma in the past 3 months | BP >180/110 mmHg not controlled; ischaemic stroke more than 3 months ago; recent major surgery or internal bleeding; traumatic or prolonged CPR; current anticoagulant; pregnancy; non-compressible vascular punctures |
Source: Therapeutic Guidelines and local retrieval protocols.5 Rural GPs should know where their local protocol and tenecteplase dosing chart are kept before they need them.
6.5 NSTEACS: risk and timing of angiography ★★★☆
For NSTEACS the decision is when to do angiography, not whether to reperfuse immediately. A routine invasive strategy is recommended for patients at high or very high risk. Lower-risk patients may instead have non-invasive testing for inducible ischaemia.1
| Risk | Features | Strategy |
|---|---|---|
| Very high | Haemodynamic instability or cardiogenic shock, ongoing or recurrent pain despite treatment, life-threatening arrhythmia or cardiac arrest, mechanical complications, acute heart failure, recurrent dynamic ST changes | Immediate invasive strategy, within 2 hours of diagnosis |
| High | Confirmed NSTEMI, dynamic ST or T changes, GRACE score >140 | Consider early invasive strategy within 24 hours |
| Lower | None of the above | Selective: test for inducible ischaemia; angiography if positive |
Fibrinolysis has no role in NSTEACS. The guideline recommends aspirin plus a potent P2Y12 inhibitor (ticagrelor or prasugrel) for patients managed invasively, and ticagrelor or clopidogrel with a selective strategy. It recommends GRACE 3.0 for risk assessment in women.1
6.6 MI that is not plaque rupture ★★☆☆
| Condition | Typical patient | Key features | Management point |
|---|---|---|---|
| Spontaneous coronary artery dissection (SCAD) | Women aged 30–60, pregnancy or postpartum, fibromuscular dysplasia, extreme exertion or emotional stress | Few risk factors; angiography shows a dissection or long smooth narrowing | Usually conservative: routine revascularisation not recommended if stable. Screen for fibromuscular dysplasia |
| MINOCA | More common in women | MI with non-obstructive coronary arteries | A working diagnosis: exclude alternatives; cardiac MRI if the cause is not obvious |
| Takotsubo syndrome | Postmenopausal women after emotional or physical stress | Apical ballooning; troponin rise out of proportion; usually recovers | Differential of ACS; covered with cardiomyopathies |
| Coronary vasospasm, cocaine or amphetamine | Younger; smokers; stimulant use | Transient ST elevation; responds to nitrates | Avoid beta-blockers in acute cocaine toxicity; benzodiazepines and nitrates |
| Myocarditis | Younger; recent viral illness; some medicines and vaccines | Troponin rise, ECG changes, normal coronaries | Cardiac MRI; avoid exertion |
Sources: 2025 ACS guideline.1
7. After an ACS: the GP’s role ★★★★
Most of the long-term benefit after an ACS comes from what happens in the months after discharge: continuing the right antiplatelet regimen for the right time, reaching the LDL-C target, attending rehabilitation and stopping smoking. The 2025 guideline stresses two-way communication between hospital and GP, and suggests a GP chronic condition management plan for people with complex needs.1 A structured review in the first one to two weeks after discharge is good practice.
7.1 Medicines after ACS ★★★★
| Medicine | Recommendation | GP points |
|---|---|---|
| DAPT: standard | Aspirin plus a P2Y12 inhibitor for 6–12 months if high ischaemic and low bleeding risk | Ticagrelor or prasugrel after PCI or invasive NSTEACS; clopidogrel after fibrinolysis, with an oral anticoagulant, or if the others are contraindicated |
| DAPT: high bleeding risk | Stop DAPT at 1–3 months and continue a single antiplatelet | High bleeding risk: older age, anaemia, CKD, previous bleeding, long-term NSAID or steroid use |
| After DAPT | Long-term P2Y12 inhibitor preferred over aspirin | New in 2025; extended DAPT beyond 12 months can be considered in high ischaemic, low bleeding risk |
| De-escalation | Switching from ticagrelor or prasugrel to clopidogrel can be considered, but not in the first 30 days | For bleeding or side effects (e.g. ticagrelor dyspnoea): discuss with the cardiologist |
| With atrial fibrillation (CHA2DS2-VASc >1) | Aspirin plus clopidogrel plus a NOAC for 1–4 weeks, then stop aspirin; stop the antiplatelet at 6–12 months and continue the anticoagulant alone | Triple therapy beyond the first month is a common prescribing error |
| Proton pump inhibitor | With DAPT if at high risk of GI bleeding; with triple therapy | Pantoprazole and esomeprazole are commonly used |
| Statin and lipids | Highest tolerated statin before discharge, for life. Target LDL-C <1.4 mmol/L and ≥50% reduction; recheck 4–6 weeks after starting or changing treatment; add ezetimibe, then a PCSK9 inhibitor if needed | Lesson 2, section 4.2 |
| Beta-blocker | Recommended with LV impairment. With preserved LV function after revascularisation on optimal therapy, withholding can be considered; no benefit seen from continuing beyond 12 months15 | A change from routine lifelong use |
| ACE inhibitor or ARB | Start and continue if heart failure symptoms, LVEF ≤40%, diabetes, hypertension or CKD | ARB if ACE inhibitor not tolerated |
| Mineralocorticoid antagonist | LVEF ≤40% with heart failure, with or without diabetes | Check potassium and eGFR |
| ARNI (sacubitril/valsartan) | Not recommended in ACS | Different from chronic HFrEF |
| Colchicine | Consider 0.5 mg daily long-term | Check kidney function and interactions |
| Semaglutide | Possible adjunct in people with overweight or obesity | Check PBS criteria |
| GTN | Short-acting spray or tablets with an action plan | Check PDE5 inhibitor use |
Source: Heart Foundation/CSANZ 2025.1 Never stop antiplatelets early on your own initiative, including for elective procedures, without discussing it with the treating cardiologist. Stopping DAPT soon after a stent is the main cause of stent thrombosis. Elective non-cardiac surgery is generally deferred until DAPT is complete; the ESC suggests waiting 12 months after an ACS when possible (at least 6 months after elective PCI).16 Advise patients to tell every dentist and doctor about their antiplatelets; most dental procedures can go ahead without stopping them.
7.2 Rehabilitation, lifestyle, vaccination and mental health ★★★☆
- Cardiac rehabilitation: refer everyone with ACS to a multidisciplinary, exercise-based program before discharge. If that is not possible (for example, in remote areas), offer a flexible alternative such as telephone, online or home-based programs. Programs speed return to usual activities, including work. For First Nations patients, enable access through Aboriginal and Torres Strait Islander health practitioners where possible.1
- Smoking: advise stopping, refer for behavioural support (Quitline) and offer pharmacotherapy. Stopping smoking is one of the most effective secondary prevention measures.
- Physical activity, diet, alcohol and weight: specific advice (for example, a walking program building to at least 30 minutes on most days; a Mediterranean-style diet; no more than 10 standard drinks a week and 4 on any day).
- Mental health: screen for depression and other mental health conditions with a validated tool (for example, PHQ-9) and refer for support as needed. Depression after ACS is common and predicts poorer outcomes.
- Vaccination: influenza and other respiratory vaccines.
- Adherence: adherence falls steeply in the first year. Use dose administration aids, pharmacist medication reviews and simple regimens.
7.3 Driving, work, sex and travel ★★★★
| Event | Private driver | Commercial driver |
|---|---|---|
| Acute myocardial infarction | At least 2 weeks | At least 4 weeks |
| PCI | At least 2 days | At least 4 weeks |
| CABG | At least 4 weeks | At least 3 months |
| Cardiac arrest | At least 6 months | At least 6 months |
Source: Austroads, Assessing Fitness to Drive.9 Where events overlap (for example, MI treated with PCI), the longer period applies. Commercial drivers usually also need specialist assessment before a conditional licence is granted; check the current standard. The patient is responsible for telling the licensing authority if their condition is likely to affect their driving; the GP must advise them of this and document the advice.
Return to work depends on the job: most people with office work return within a few weeks of an uncomplicated event, and manual or safety-sensitive work needs individual assessment. Sexual activity can usually resume once the patient can manage moderate exertion without symptoms. Address it directly, because many patients are too worried to ask, and check for PDE5 inhibitor use and the interaction with nitrates.
7.4 Common prescribing problems ★★☆☆
| Problem | Correct approach |
|---|---|
| Breathlessness on ticagrelor | Common and usually mild; exclude heart failure and anaemia. If intolerable, discuss switching with the cardiologist (not in the first 30 days unless essential) |
| Patient wants an NSAID for back pain | Avoid NSAIDs, especially early after ACS and on DAPT; use paracetamol and non-drug measures |
| Minor bleeding on DAPT (bruising, nosebleeds) | Reassure; continue DAPT; check FBC if persistent. Major bleeding: urgent hospital review |
| Patient on clopidogrel needs a PPI | Pantoprazole is usually preferred (omeprazole and esomeprazole may reduce clopidogrel activation) |
| Dental extraction on DAPT | Usually proceed without stopping; local haemostatic measures |
| New AF after ACS | Anticoagulate if CHA2DS2-VASc >1; regimen per Table 15 with the cardiologist |
8. Special populations ★★★☆
| Group | What differs | What to do |
|---|---|---|
| Aboriginal and Torres Strait Islander people | Coronary disease occurs earlier and more often; access to PCI and rehabilitation is often limited; rheumatic heart disease and diabetes are common co-conditions | CVD risk assessment from age 30 (Lesson 1); involve Aboriginal health practitioners and liaison officers early; culturally appropriate interpreters; rehabilitation through Aboriginal community controlled services1,18 |
| Women | More often misdiagnosed and undertreated; SCAD, MINOCA, INOCA and Takotsubo are more common | Take chest pain seriously; start statins when indicated (women are less often prescribed them after ACS); tailor rehabilitation to improve attendance |
| Older people | Breathlessness, fatigue or dizziness may replace chest pain; higher bleeding risk | Consider shortened DAPT; half-dose tenecteplase if aged ≥70; review falls and polypharmacy |
| Diabetes | Silent or atypical ischaemia; worse outcomes | ACE inhibitor or ARB; SGLT2 inhibitor or GLP-1 receptor agonist with proven CV benefit; CABG often preferred for multivessel disease |
| Chronic kidney disease | Chronically raised troponin; contrast and bleeding risk | Use serial troponin change, not one value; dose-adjust drugs |
| Pregnancy and postpartum | SCAD is the leading cause of pregnancy-associated MI | Treat chest pain in a pregnant or postpartum woman as possible ACS |
| Rural and remote | Long distances to PCI; the GP may give fibrinolysis | Know the local retrieval number and tenecteplase protocol; prehospital fibrinolysis; telehealth cardiology support |
In rural KFP cases, “transfer to hospital” is rarely enough. Expect to be asked what you will do in the next 30 minutes with the PCI centre several hours away: ECG, aspirin, call retrieval, screen for fibrinolysis contraindications, and tenecteplase (half dose if aged 70 or older) with clopidogrel and enoxaparin, then transfer for angiography within 2–24 hours.
9. Old versus new guidance ★★★★
Exam questions are written to current guidelines and often use the superseded answer as a distractor. The 2016 Australian ACS guideline was the reference for nearly a decade, so most older notes, question banks and the source guide for this course still contain its values.21
| Topic | Old teaching (2016) | Current (2025) |
|---|---|---|
| Terminology | STEMI / NSTEACS | ACOMI (STEMI and STEMI equivalents) / NSTEACS |
| Oxygen | If SpO2 <93% | Only if SpO2 <90%; do not exceed 96% |
| PCI or fibrinolysis | PCI if first medical contact to device ≤90 minutes (≤120 with transfer) | PCI if achievable within 120 minutes of first medical contact; otherwise fibrinolysis within 30 minutes |
| Tenecteplase in older people | Full weight-based dose | Half dose if aged ≥70 (pharmaco-invasive strategy) |
| NSTEACS angiography | Intermediate risk within 72 hours | Very high risk <2 hours; high risk consider <24 hours; lower risk selective |
| DAPT | 12 months for most | 6–12 months; 1–3 months if high bleeding risk; then P2Y12 inhibitor preferred long term |
| Beta-blockers | Routine for all after MI | For LV impairment; can be withheld with preserved LV function |
| LDL-C target | <1.8 mmol/L | <1.4 mmol/L and ≥50% reduction |
| Colchicine | Not recommended | Consider 0.5 mg daily long term |
| LBBB | New LBBB treated as STEMI | Use modified Sgarbossa criteria |
From the RACGP KFP 2025.1 public exam report19
- Acute chest pain with an ECG: in a case of acute pericarditis in a young Aboriginal man, the common error was misdiagnosing an acute myocardial infarction, which led to incorrect management. Read the ECG for the pattern, not just “ST elevation”.
- Medicines in that case: some candidates gave two NSAIDs at the same time, which was not indicated.
- Answer technique: give only the number of answers requested (extra answers are penalised), be specific, and answer using all the information in the scenario.
Other common traps
- Giving oxygen to a patient with SpO2 95%, or writing “oxygen” reflexively in an immediate-management list.
- Sending a patient with possible ACS home after one normal ECG or a negative point-of-care troponin.
- Continuing triple therapy (two antiplatelets plus an anticoagulant) for months instead of stopping aspirin after 1–4 weeks.
- Using the male V2–V4 ST-elevation threshold (2 mm) for a woman (1.5 mm).
10. Worked case (KFP style)
Robert Nguyen, aged 67 years, visits your suburban practice. Over the past 3 days he has had four episodes of central chest tightness at rest, each lasting 10–15 minutes. The last episode was 2 hours ago. He is pain-free now. He has type 2 diabetes and hypertension and smokes 10 cigarettes a day. Medicines: metformin, perindopril. He takes no other medicines. Pulse 84 regular, BP 152/88 mmHg, SpO2 97% on room air. Heart sounds normal, chest clear. The ECG shows 1 mm horizontal ST depression in V4–V6. You have no previous ECG for comparison.
Question 1. What is your immediate management in the practice? List up to four.
Show answer
- Call 000 for ambulance transfer to the emergency department.
- Aspirin 300 mg chewed (after checking for allergy or contraindication).
- Continuous monitoring with a defibrillator available; stay with the patient.
- Repeat the ECG every 15–30 minutes, or immediately if pain recurs.
- Sublingual GTN if pain recurs (after checking BP and PDE5 inhibitor use).
Rest pain in a crescendo pattern with ischaemic ST depression is NSTEACS until proven otherwise. Scores zero: oxygen (SpO2 97%), point-of-care troponin to decide on transfer, outpatient stress testing, referral to a cardiologist next week, letting him drive himself to hospital.
Robert has an NSTEMI. Angiography shows a 90% mid-LAD stenosis, treated with a drug-eluting stent. LVEF is 58%. He is discharged 3 days later and sees you a week after discharge. He has no other bleeding risk factors and no history of AF.
Question 2. List up to five medicines that should be part of his regimen now (in addition to metformin).
Show answer
- Aspirin 100 mg daily.
- Ticagrelor 90 mg twice daily (or prasugrel), as part of DAPT for 6–12 months.
- High-intensity statin (e.g. atorvastatin 80 mg daily).
- Continue perindopril (indicated by diabetes and hypertension).
- Sublingual GTN spray as needed, with an action plan.
Also accepted: colchicine 0.5 mg daily; an SGLT2 inhibitor or GLP-1 receptor agonist with proven CV benefit for diabetes. Not required: a beta-blocker (LVEF 58%, revascularised, no angina or arrhythmia), although continuing one started in hospital is not wrong. Scores zero: clopidogrel as first choice without a reason, warfarin, sacubitril/valsartan, NSAIDs.
Six weeks later his LDL-C is 1.7 mmol/L (baseline 3.6 mmol/L) on atorvastatin 80 mg. He has stopped smoking. He asks when he can drive his car and whether he can use the tadalafil a friend gave him.
Question 3. What is the most appropriate change to his lipid-lowering therapy? Write one answer.
Show answer
- Add ezetimibe 10 mg daily to atorvastatin 80 mg.
He has a 53% reduction but LDL-C is above 1.4 mmol/L, so he is not at target. Scores zero: doubling the statin (already maximal), starting a PCSK9 inhibitor before ezetimibe, “no change”.
Question 4. List up to three important pieces of advice about driving and tadalafil.
Show answer
- He may drive a private car now: the minimum is 2 weeks after MI and 2 days after PCI, and both have passed.
- Do not take GTN within 48 hours of tadalafil, and tell ambulance staff he has taken it if chest pain occurs.
- Do not use medicines prescribed for someone else; erectile dysfunction will be assessed and treated with him (consider whether his medicines are contributing).
Scores zero: “no driving for 6 weeks”, “tadalafil is safe with GTN”, telling him he must never have sex again.
11. Self-check questions
These questions are written at or above AKT difficulty. Every option is plausible and the options are deliberately similar. Commit to an answer before revealing the explanation.
Colin Murray, aged 74 years, presents to your rural hospital emergency department with 80 minutes of severe central chest pain. He has hypertension and no other history. Pulse 92 regular, BP 148/86 mmHg, SpO2 95% on room air. The ECG shows 3 mm ST elevation in II, III and aVF with reciprocal ST depression in I and aVL. He has had aspirin 300 mg. The retrieval service advises that the earliest he can reach the catheter laboratory is 3.5 hours from now. He has no contraindications to fibrinolysis.
What is the MOST appropriate reperfusion plan?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: D. Half-dose tenecteplase, then transfer for angiography
Feedback: This question requires candidates to apply the 120-minute rule for choosing reperfusion and the age-specific fibrinolytic dose. He has an inferior ACOMI within 12 hours, PCI is not achievable within 120 minutes of first medical contact, and he has no contraindications, so fibrinolysis should be given within 30 minutes. Because he is aged 74, the 2025 guideline recommends half-dose tenecteplase as part of a pharmaco-invasive strategy, with clopidogrel and an anticoagulant, then transfer for angiography within 2–24 hours.
- Await high-sensitivity troponin, then transfer for PCI: troponin must never delay reperfusion in ACOMI.
- Clopidogrel and enoxaparin, then transfer for angiography: these are adjuncts to fibrinolysis, not reperfusion; transfer alone would mean more than 3.5 hours of occlusion.
- Full-dose tenecteplase, then transfer for angiography: correct for a patient under 70; at 74 the dose is halved to reduce intracranial haemorrhage.
- Immediate transfer for primary PCI at the regional centre: PCI cannot be performed within 120 minutes of first medical contact.
Reference: Heart Foundation/CSANZ ACS guideline 2025.
Priya Raman, aged 56 years, has 3 months of central chest tightness when she walks uphill, settling within 5 minutes of rest. She has hypertension and dyslipidaemia and does not smoke. She cannot walk on a treadmill because of severe bilateral knee osteoarthritis. Her resting ECG is normal, with sinus rhythm at 62/min. eGFR is 85 mL/min/1.73 m2 and she has no allergies. You estimate a moderate (>15–50%) likelihood of obstructive coronary disease. The main question is whether she has obstructive coronary disease.
What is the MOST appropriate investigation?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: B. CT coronary angiography (CTCA)
Feedback: This question requires candidates to match the test to the clinical question and to the patient’s limitations. At moderate likelihood, when the aim is to rule out obstructive disease, CTCA is preferred. She is a good candidate: slow regular rhythm, normal kidney function, no contrast allergy. (For Medicare funding, CTCA must be requested by a specialist.)
- Coronary artery calcium score: adjusts likelihood but does not show non-calcified plaque or stenosis, so it cannot answer the question in a symptomatic patient.
- Dobutamine stress echocardiography: appropriate if the question were whether ischaemia explains the symptoms (e.g. known disease); CTCA is preferred for ruling out obstruction.
- Exercise treadmill stress ECG: she cannot exercise adequately, and its accuracy is lower.
- Invasive coronary angiography: reserved for very high likelihood, severe symptoms or high-risk non-invasive results.
Reference: ESC chronic coronary syndromes guideline 2024; MBS item 57360.
Graham Ellis, aged 66 years, has stable angina on exertion two or three times a week despite metoprolol 50 mg twice daily. He had an anterior MI 2 years ago and his LVEF is 38%. Today his pulse is 54 regular and BP is 148/90 mmHg on two readings. He takes tadalafil for erectile dysfunction about once a week. Other medicines: aspirin, atorvastatin, perindopril, spironolactone.
What is the MOST appropriate addition to his treatment?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: A. Amlodipine 5 mg once daily
Feedback: This question requires candidates to choose an add-on antianginal under several constraints at once. A dihydropyridine calcium channel blocker is the standard addition to a beta-blocker. It is safe in reduced LVEF and also treats his uncontrolled BP.
- Diltiazem CD 180 mg once daily: rate-limiting CCBs are avoided with a beta-blocker (pulse already 54) and with LVEF ≤40%.
- Isosorbide mononitrate 60 mg mane: contraindicated with regular tadalafil use (severe hypotension).
- Ivabradine 5 mg twice daily: needs a resting heart rate of at least 70/min in sinus rhythm; his is 54.
- Nicorandil 10 mg twice daily: also contraindicated with PDE5 inhibitors, and it does not address his hypertension.
Reference: Therapeutic Guidelines: Cardiovascular; AMH.
Leonie Hart, aged 61 years, had an NSTEMI treated with a drug-eluting stent 4 months ago. She takes aspirin 100 mg and ticagrelor 90 mg twice daily, with a 12-month DAPT plan from her cardiologist. She has a small, reducible, painless inguinal hernia, and a surgeon has offered an elective repair next month. The surgeon asks you to stop both antiplatelets beforehand. She has no symptoms of obstruction and is happy to wait.
What is the MOST appropriate management of her antiplatelet therapy?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: B. Defer the hernia repair until DAPT is completed
Feedback: This question requires candidates to protect a recent stent when surgery is truly elective. Four months after an ACS with a drug-eluting stent, stopping antiplatelets risks stent thrombosis. Her hernia is uncomplicated and she is willing to wait, so the procedure should be deferred until DAPT is complete (12 months after ACS where possible).
- Bridge with enoxaparin while both are stopped: heparin does not protect a stent from platelet-mediated thrombosis.
- Stop aspirin and ticagrelor 7 days before surgery: stopping both antiplatelets early after a stent carries the highest thrombosis risk.
- Stop ticagrelor 5 days before, continue aspirin: the correct approach if surgery could not wait, after discussion with the cardiologist; not for a deferrable procedure.
- Switch ticagrelor to clopidogrel 5 days before: clopidogrel also increases surgical bleeding and does not solve the timing problem.
Reference: ESC non-cardiac surgery guideline 2022; Heart Foundation/CSANZ ACS guideline 2025.
Hannah Okafor, aged 44 years, attends your clinic with 40 minutes of central chest pressure radiating to her left arm. She is sweaty. Pulse 96 regular, BP 132/80 mmHg, SpO2 98% on room air. The ECG shows new ST elevation of 1.6 mm in V2, V3 and V4 with upright T waves, and no other changes. A repeat ECG 10 minutes later is unchanged and her pain persists.
What is the MOST appropriate interpretation and action?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: C. Meets ACOMI criteria; activate the reperfusion pathway
Feedback: This question requires candidates to apply the sex-specific ST-elevation threshold in V2–V4. In women, ST elevation of ≥1.5 mm in V2–V4 meets the ACOMI criterion (men aged ≥40 years need ≥2 mm). She has new, persistent elevation in contiguous anterior leads with ongoing ischaemic pain, so reperfusion is needed now.
- Below the female threshold; repeat ECG in 15 minutes: 1.6 mm is above the female threshold of 1.5 mm; 2 mm is the male threshold.
- Benign early repolarisation; repeat ECG in 15 minutes: the elevation is new, accompanied by ongoing typical pain and sweating; never label it benign in this context.
- Possible ACOMI; await the 2-hour hs-troponin result: troponin must not delay reperfusion when the ECG shows occlusion.
- Posterior ACOMI pattern; record leads V7 to V9 now: posterior MI shows ST depression in V1–V3, not elevation.
Reference: Heart Foundation/CSANZ ACS guideline 2025.
Sophie Laurent, aged 36 years, sees you 2 weeks after a hospital admission. She is 4 months postpartum and breastfeeding. She developed sudden severe chest pain during a gym session. Her hs-troponin rose from 40 ng/L to 860 ng/L* (reference <16 ng/L) and her ECG showed anterior T-wave inversion. She has no cardiovascular risk factors. Angiography showed a long, smooth, tapering narrowing of the mid LAD that did not change after intracoronary GTN, with no atherosclerosis elsewhere. Her LV function is normal apart from mild anterior hypokinesia, and there is no apical ballooning. CTPA was normal.
What is the MOST likely diagnosis?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: F. Spontaneous coronary dissection
Feedback: This question requires candidates to recognise SCAD, the leading cause of pregnancy-associated MI. The clues are a young postpartum woman without risk factors, extreme exertion as a trigger, a type 1 pattern of troponin rise, and the angiographic appearance of a long smooth narrowing (intramural haematoma) that does not respond to nitrate, with no atherosclerosis elsewhere.
- Acute idiopathic pericarditis: would show pleuritic positional pain, widespread ST elevation and a normal angiogram.
- Acute pulmonary embolism: excluded by a normal CTPA.
- Acute viral myocarditis: coronaries are normal; she has a focal coronary lesion matching the wall-motion abnormality.
- Coronary artery vasospasm: spasm resolves with intracoronary GTN; this narrowing did not.
- Paradoxical coronary embolism: usually an abrupt cut-off in a distal vessel, often with AF or a shunt, not a long tapering narrowing.
- Takotsubo stress cardiomyopathy: typically postmenopausal, with apical ballooning beyond a single coronary territory.
- Type A aortic dissection: tearing back pain, pulse differences and an abnormal aorta; not a mid-LAD lesion.
Reference: Heart Foundation/CSANZ ACS guideline 2025.
Mark Delaney, aged 59 years, had an inferior STEMI treated with primary PCI 14 months ago. His LVEF on the latest echocardiogram is 60%. He has no angina, no arrhythmia and no heart failure. He takes clopidogrel, atorvastatin 80 mg, ramipril and bisoprolol 2.5 mg daily. He reports fatigue and erectile dysfunction since starting bisoprolol and asks whether he still needs it. Pulse 58 regular, BP 122/76 mmHg. LDL-C is 1.2 mmol/L.
What is the MOST appropriate management of his bisoprolol?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: E. Taper and stop bisoprolol over 1 to 2 weeks
Feedback: This question requires candidates to apply the 2025 change in beta-blocker advice after ACS. With preserved LV function after revascularisation, on optimal therapy and with no other indication (no angina, arrhythmia, heart failure or uncontrolled BP), beta-blockers can be withheld, and no benefit has been seen from continuing them beyond 12 months. His side effects tip the balance. Taper rather than stop abruptly.
- Continue bisoprolol; review again in 12 months: reflects the old routine lifelong approach; it continues a drug that is causing side effects with no expected benefit.
- Halve bisoprolol; recheck heart rate in 4 weeks: leaves him on a drug he does not need.
- Switch bisoprolol to ivabradine 5 mg twice daily: ivabradine needs a heart rate of ≥70/min, and he has no angina to treat.
- Switch bisoprolol to nebivolol 1.25 mg daily: continues beta-blockade without an indication.
Reference: Heart Foundation/CSANZ ACS guideline 2025; REDUCE-AMI trial 2024.
Anthony Russo, aged 61 years, walks into your clinic at 9 am. At 7.30 am he had 25 minutes of central chest heaviness while sitting at breakfast, with sweating. It settled without treatment. He has type 2 diabetes and smokes. He is now pain-free. Pulse 78, BP 138/84 mmHg, SpO2 97%. His ECG is normal. A point-of-care troponin I in your clinic is below the detection limit.
What is the MOST appropriate next step?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: D. Send by ambulance to ED for serial hs-troponin
Feedback: This question requires candidates to recognise that a normal ECG and a negative point-of-care troponin cannot exclude ACS. He had 25 minutes of rest pain with sweating and two major risk factors, so this is a possible ACS. Symptom onset was 90 minutes ago, too early for even a single high-sensitivity result to rule out MI, and point-of-care assays are less sensitive. He needs serial hs-troponin and risk scoring in the ED, transported by ambulance, with aspirin given.
- Arrange outpatient stress testing within 2 weeks: appropriate for stable angina, not rest pain within the past 2 hours.
- Refer for CT coronary angiography this week: outpatient CTCA is not the test for possible ACS.
- Repeat the point-of-care troponin in 3 hours: keeps a possible ACS in an unmonitored setting with a less sensitive assay.
- Start aspirin and review in the clinic tomorrow: aspirin is right, but sending him home is unsafe.
Reference: Heart Foundation/CSANZ ACS guideline 2025.
Beryl Thompson, aged 72 years, has non-valvular AF (CHA2DS2-VASc score 4) and takes apixaban 5 mg twice daily. Six weeks ago she had an NSTEMI treated with a drug-eluting stent. The discharge summary lists apixaban, aspirin 100 mg and clopidogrel 75 mg, with no stop dates or other plan. She has no bleeding and no new symptoms. Her cardiologist cannot be reached this week. eGFR is 58 mL/min/1.73 m2, weight 68 kg, creatinine 98 µmol/L.
What is the MOST appropriate change to her antithrombotic therapy?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: C. Stop aspirin; continue apixaban and clopidogrel
Feedback: This question requires candidates to know the triple-therapy rule after ACS in a patient with AF. Aspirin, clopidogrel and a NOAC are given for 1–4 weeks only; aspirin is then stopped, and clopidogrel plus the anticoagulant continue to 6–12 months, followed by the anticoagulant alone. At 6 weeks she is past the triple-therapy window, and every extra week increases bleeding risk. Inform the cardiologist of the change. Her apixaban dose is correct (she meets none of the dose-reduction criteria).
- Continue all three until 12 months after PCI: prolonged triple therapy greatly increases bleeding without reducing ischaemic events.
- Stop apixaban; continue aspirin and clopidogrel: leaves her stroke risk (CHA2DS2-VASc 4) unprotected.
- Stop clopidogrel; continue apixaban and aspirin: the guideline keeps clopidogrel, not aspirin, with the anticoagulant.
- Switch clopidogrel to ticagrelor with apixaban: potent P2Y12 inhibitors are not used with an anticoagulant because of bleeding risk.
Reference: Heart Foundation/CSANZ ACS guideline 2025.
Wayne Barker, aged 54 years, is a long-haul truck driver. Ten days ago he had an inferior STEMI treated with primary PCI and a single stent. His recovery has been uncomplicated, LVEF is 55%, and he has no angina or arrhythmia. He asks when he can return to driving his truck. He also holds a private licence.
What is the MOST appropriate advice about commercial driving?
Show answer
You were sure, but wrong. Confident errors are the most dangerous kind, because they never get revised. Re-read the section below today.
Right, but you guessed. Treat this as not yet learnt.
Sure and right — this one is secure.
Answer: D. No commercial driving for at least 4 weeks
Feedback: This question requires candidates to apply the Austroads commercial standards and combine two overlapping events. After an AMI, commercial drivers should not drive for at least 4 weeks, and the same minimum applies after PCI. A conditional licence then depends on specialist assessment against the commercial standard.
- No commercial driving for at least 2 days: the private standard after PCI alone.
- No commercial driving for at least 2 weeks: the private standard after AMI.
- No commercial driving for at least 3 months: the commercial standard after CABG.
- No commercial driving for at least 6 months: the standard after cardiac arrest (or after ICD implantation for commercial drivers).
Reference: Austroads, Assessing Fitness to Drive (cardiovascular conditions).
Self-check score: / 10
Sure but wrong:
Any “sure but wrong” answer is your highest exam risk. Re-read those sections first, then use the flashcards below. Your selections are not saved; the score resets when you leave the page.
Tick each one you can do without notes. Anything left unticked is your revision list.
- Not yet? Re-read section 6.3 →
- Not yet? Re-read section 6.1 →
- Not yet? Re-read section 6.4 →
- Not yet? Re-read section 6.2 →
- Not yet? Re-read section 5.2 →
- Not yet? Re-read section 4.2 →
- Not yet? Re-read section 7.1 →
- Not yet? Re-read section 7.3 →
Ready on of 8.
12. Key takeaways
- Terminology: ACOMI = STEMI and STEMI equivalents (posterior, RV, De Winter, Sgarbossa-positive LBBB or paced rhythm): reperfuse now.
- ECG: within 10 minutes. ST elevation ≥1 mm in contiguous leads; in V2–V4, ≥1.5 mm in women and ≥2 mm in men aged ≥40.
- In the practice: call 000, aspirin 300 mg chewed, GTN every 5 minutes up to 3 doses if no contraindication, oxygen only if SpO2 <90%, no NSAIDs, never by private car.
- Troponin: serial hs-cTn on a 0/1 or 0/2-hour pathway; one result is not enough within 2 hours of onset; a negative point-of-care result does not rule out ACS.
- Reperfusion: primary PCI if within 120 minutes of first medical contact; otherwise fibrinolysis within 30 minutes (tenecteplase half dose if aged ≥70), then angiography in 2–24 hours.
- NSTEACS: very high risk <2 hours, high risk consider <24 hours; no fibrinolysis.
- DAPT: 6–12 months (1–3 months if high bleeding risk), then long-term P2Y12 inhibitor preferred; no de-escalation in the first 30 days.
- With AF: triple therapy for 1–4 weeks only, then clopidogrel plus NOAC to 6–12 months, then NOAC alone.
- Lipids and beta-blockers: LDL-C <1.4 mmol/L and ≥50% reduction; beta-blockers for LV impairment, not routinely with preserved LVEF.
- Stable angina: beta-blocker or CCB first line; no verapamil or diltiazem with a beta-blocker or reduced LVEF; no nitrates or nicorandil with PDE5 inhibitors (24 h sildenafil or vardenafil, 48 h tadalafil); ivabradine needs a heart rate of ≥70/min.
- Testing: CTCA to rule out obstructive disease at low–moderate likelihood (Medicare requires a specialist request); functional imaging to link symptoms to ischaemia.
- Driving: AMI: private 2 weeks, commercial 4 weeks. PCI: 2 days and 4 weeks. CABG: 4 weeks and 3 months.
Your revision plan
| When | What to do |
|---|---|
| Today | Finish the lesson, both question sets and the readiness checklist. Note every “sure but wrong” answer. |
| Day 3 | Do this lesson’s 10 flashcards again (end of this lesson). Re-read every section you marked “Not yet”. |
| Day 7 | Redo the self-check questions without looking at the lesson. Aim for 8/10 with no “sure but wrong”. |
| Day 21 | Do the cardiovascular chapter flashcard deck, then one timed block of mixed questions at exam pace. |
| Week before the exam | Re-read the key takeaways, Table 19 and the old-notes box. Do the chapter flashcard deck once more. |
Your next step
Use your scores from the cold-start check and the self-check questions to choose your next step.
Flashcards: 10 high-yield recall cards
Finish the lesson by testing your recall. Say the answer out loud before you tap the card to flip it, then mark “I knew this” only if you were fully right without looking. Repeat the cards on day 3 and day 21, and use the cardiovascular chapter deck for later reviews.
13. References and recommended reading
References
- Brieger DB, Cullen LA, Briffa TG, et al. National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: comprehensive Australian clinical guideline for diagnosing and managing acute coronary syndromes 2025. Heart Lung Circ 2025. heartlungcirc.org (accessed 10 Nov 2026).
- Brieger DB, Cullen LA, Briffa TG, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guideline for diagnosing and managing acute coronary syndromes 2025 [summary]. Med J Aust 2026;224(2). doi:10.5694/mja2.70127. mja.com.au (accessed 10 Nov 2026).
- National Heart Foundation of Australia. ACS guideline and clinical resources. heartfoundation.org.au (accessed 10 Nov 2026).
- Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J 2024;45:3415–537.
- Therapeutic Guidelines. Cardiovascular (current version): angina, acute coronary syndromes. Melbourne: Therapeutic Guidelines Limited. tg.org.au (accessed 10 Nov 2026).
- Australian Medicines Handbook. Adelaide: AMH Pty Ltd (current edition): nitrates; phosphodiesterase-5 inhibitors; nicorandil; ivabradine. amhonline.amh.net.au (accessed 10 Nov 2026).
- Australian Government Department of Health, Disability and Ageing. MBS Online: item 57360 (CT coronary angiography). mbsonline.gov.au (accessed 10 Nov 2026).
- Medical Republic. New CT angiography item on table six years after recommendation. June 2024. medicalrepublic.com.au (accessed 10 Nov 2026).
- Austroads. Assessing Fitness to Drive for commercial and private vehicle drivers. Part B, section 2: Cardiovascular conditions. austroads.gov.au (accessed 10 Nov 2026).
- National Heart Foundation of Australia. Heart attack warning signs: action plan (fact sheet). heartfoundation.org.au (accessed 10 Nov 2026).
- Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Circulation 2018;138:e618–51.
- Maron DJ, Hochman JS, Reynolds HR, et al (ISCHEMIA). Initial invasive or conservative strategy for stable coronary disease. N Engl J Med 2020;382:1395–407.
- Nidorf SM, Fiolet ATL, Mosterd A, et al (LoDoCo2). Colchicine in patients with chronic coronary disease. N Engl J Med 2020;383:1838–47.
- Eikelboom JW, Connolly SJ, Bosch J, et al (COMPASS). Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377:1319–30.
- Yndigegn T, Lindahl B, Mars K, et al (REDUCE-AMI). Beta-blockers after myocardial infarction and preserved ejection fraction. N Engl J Med 2024;390:1372–81.
- Halvorsen S, Mehilli J, Cassese S, et al. 2022 ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J 2022;43:3826–924.
- Australian Institute of Health and Welfare. Heart, stroke and vascular disease: Australian facts. aihw.gov.au (accessed 10 Nov 2026).
- NACCHO and RACGP. National guide to preventive healthcare for Aboriginal and Torres Strait Islander people (current edition). racgp.org.au (accessed 10 Nov 2026).
- The Royal Australian College of General Practitioners. KFP 2025.1 public exam report. Melbourne: RACGP; 2025. racgp.org.au (accessed 10 Nov 2026).
- The Royal Australian College of General Practitioners. AKT and KFP: general exam delivery information. racgp.org.au (accessed 10 Nov 2026).
- Chew DP, Scott IA, Cullen L, et al. National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016. Heart Lung Circ 2016;25:895–951. (Superseded; cited for comparison.)
Recommended reading for RACGP fellowship candidates
- Heart Foundation/CSANZ ACS guideline 2025 and its MJA summary — the source of current AKT answers for ACS; read the practice points and the antiplatelet algorithms.
- Therapeutic Guidelines: Cardiovascular — angina, ACS and fibrinolysis chapters for Australian drug choices and doses.
- Australian Medicines Handbook — antianginal contraindications and interactions (nitrates, nicorandil, ivabradine, verapamil and diltiazem).
- Austroads, Assessing Fitness to Drive — cardiovascular chapter; frequently examined.
- Heart Foundation heart attack action plan — the wording you should teach patients.
- Murtagh’s General Practice — chest pain chapter for the diagnostic approach in general practice.
- RACGP check and AJGP — chest pain and secondary prevention units; RACGP curriculum: cardiovascular health.
- NACCHO–RACGP National Guide — cardiovascular prevention for Aboriginal and Torres Strait Islander people.
Version history
| Version | Date | Changes |
|---|---|---|
| 2026–27 (v1.0) | 10 Nov 2026 | First edition, with engagement layer, flashcards and study-priority stars. Based on the 2025 Heart Foundation/CSANZ ACS guideline, 2024 ESC chronic coronary syndromes guideline, MBS item 57360 and Austroads cardiovascular standards. |
© GP Institute of Australia. For educational use by enrolled candidates only; not for redistribution. This lesson summarises Australian guidelines for exam preparation and does not replace current clinical guidelines or clinical judgement. Always check doses and PBS restrictions in current Therapeutic Guidelines, AMH and the PBS Schedule.